Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nutri/System using Prozac/phentermine combo in place of "phen/fen" for obesity; Jenny Craig ends Rx use.

Executive Summary

PROZAC5/PHENTERMINE TO REPLACE "FEN/PHEN" AT NUTRI/SYSTEM centers offering pharmacologic therapy for obesity, the weight loss center company said. The decision follows another round of negative publicity for the unapproved fenfluramine/phentermine combination and the approved fenfluramine isomer dexfenfluramine, sold as Redux by Wyeth-Ayerst and Interneuron. Lilly's Prozac (fluoxetine) and fenfluramine both affect serotonin levels in the brain; however, fluoxetine is a selective serotonin reuptake inhibitor, while fenfluramine is a serotonin reuptake inhibitor and releasing agent.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel